Program
ethyl LEUCYL-1-METHYL-D-TRYPTOPHANATE
Also written as “NLG802 (indoximod Prodrug)” and “NLG802”.
Its studies are mostly in Brain Neoplasms, led by Lumos Pharma.
Drug pageEthyl LEUCYL-1-METHYL-D-TRYPTOPHANATE: every studyAll 3 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Lumos Pharma | 21 open or running | phase 1since May 22, 2017 | May 22, 2017 | Oct 8, 2030phase 1 · NCT07732413 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 22, 2017First study: phase 1 study in Solid TumorFirst studyNCT03164603 · 26 enrolled · United States
- Jul 20, 2026Phase 1 study in Progressive Pediatric Brain CancerNCT07732413 · 30 planned · United States
Ahead
- Oct 8, 2030Primary completion: phase 1 study in Progressive Pediatric Brain CancerNCT07732413
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07732413Progressive Pediatric Brain Cancer · United States | 1 | Not yet recruiting | Oct 8, 2030 | 30 |
| NCT03164603Solid Tumor · United States | 1 | Completed | Apr 1, 2019 | 26 |
How it is read
Names in the registry
- “NLG802 (indoximod Prodrug)”, 1 entry
- “NLG802”, 1 entry
Conditions, from the studies’ own filings
- Brain Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.